Aclarion Inc. (Nasdaq: ACON), a Broomfield-based healthcare technology company, reported a 132% year-over-year increase in scan volume for its flagship product, Nociscan, from Q2 2024 to Q2 2025. This marks the company’s first time achieving two consecutive quarters of scan growth.
Nociscan uses proprietary AI algorithms and magnetic resonance spectroscopy to help physicians identify the source of chronic low back pain. The scan is now covered by three of the top four private insurers in the U.K., opening access to more than 5 million patients. Aclarion credits its international growth strategy — starting with The London Clinic — for driving much of the recent volume increase.
Aclarion is also progressing with its pivotal CLARITY trial, aimed at demonstrating Nociscan’s ability to improve surgical outcomes. The first patient was enrolled in June at the Texas Back Institute. The trial will include 300 patients across eight U.S. sites, with early clinical outcome data expected in Q2 2026.
The company also announced it is fully funded through Q3 2026 after raising $15 million earlier this year and eliminating all debt.
CEO Brent Ness said the strong scan growth and positive insurer response “validate our strategy and fuel our confidence” in broader adoption.
Aclarion currently holds 24 U.S. patents and is exploring the possibility of spinning off new ventures based on its intellectual property.
